NLRP3 inflammasome blockade significantly prevents α-syn-induced microglial activation and IL-1β production, preventing neuronal damage of midbrain DA neurons, ultimately improving the symptoms in patients with Parkinson’s disease [99]. Here, IL1B is linked to Parkinson disease.